CEL-SCI (CVM) - סך הכנסות החברה

CEL-SCI Corporation is developing the Multikine immuno-oncology complex for the therapy of head and neck tumors. The company's operations remain independent of market cycles, as demand for cancer treatment remains stable. However, relying on a single product creates risks associated with the FDA verdict. The dynamics of the company's total realization on the GURU.Markets chart demonstrate the revenue trend, where 0.00 determines the latest valuation metric.

For CEL-SCI Corporation (CVM), sales revenue serves as a key indicator of operational viability amid prolonged clinical trials. This metric aggregates all cash inflows from commercial transactions per day, allowing the company to filter out market noise and identify real revenue dynamics. The calculation is based on the summation of actual payments, revealing the gap between market capitalization and actual cash flow. In an environment of acute capital shortages and share dilution, this chart becomes a critical tool for monitoring the issuer's survival.